Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

Background: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical and biochemical response induced by originator af...

Full description

Bibliographic Details
Main Authors: Davide Massimi, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Antonio Ferronato, Sonia Facchin, Romilda Cardin, Linda Cingolani, Cesare Casadei, Renata D’Incà, Fabiana Zingone, Edoardo Vincenzo Savarino
Format: Article
Language:English
Published: SAGE Publishing 2021-06-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848211023384

Internet

https://doi.org/10.1177/17562848211023384

Similar Items